171 related articles for article (PubMed ID: 37500898)
1. Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma.
Gong C; Wu J; Song W; Li H; Shi C; Gao Y; Shi Z; Li Z; Zhang M
Ann Hematol; 2023 Oct; 102(10):2845-2855. PubMed ID: 37500898
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma.
Wu J; Shi C; Li H; Song W; Huang S; Zhang J; Li W; Li Z; Zhang M
BMC Med; 2023 Jul; 21(1):253. PubMed ID: 37442994
[TBL] [Abstract][Full Text] [Related]
3. The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma.
Gao Y; Feng X; Song W; Li H; Shi C; Jin M; Li Z; Zhang L; Zhang M
Hematol Oncol; 2022 Oct; 40(4):678-688. PubMed ID: 35439335
[TBL] [Abstract][Full Text] [Related]
4. Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells.
Li X; Yuan X; Wang Z; Li J; Liu Z; Wang Y; Wei L; Li Y; Wang X
Front Oncol; 2022; 12():819714. PubMed ID: 35251986
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
[TBL] [Abstract][Full Text] [Related]
7. Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Luo J; Dai X; Hu H; Chen J; Zhao L; Yang C; Sun J; Zhang L; Wang Q; Xu S; Xu Y; Liu N; Ying G; Wang P
J Cancer Res Clin Oncol; 2020 Mar; 146(3):721-737. PubMed ID: 31786739
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P
EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
[TBL] [Abstract][Full Text] [Related]
10. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
11. Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma.
Zhang P; Shi C; Song Y; Li Z; Zhang M; Jin M
Hematol Oncol; 2022 Dec; 40(5):941-952. PubMed ID: 35797410
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
13. Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells.
He C; Wang C; Liu H; Shan B
BMC Cancer; 2022 Jul; 22(1):724. PubMed ID: 35778693
[TBL] [Abstract][Full Text] [Related]
14. Sonidegib, a Smoothened Inhibitor, Promotes Apoptosis and Suppresses Proliferation of Natural Killer/T-Cell Lymphoma.
Liu S; Li C; Xin P; Zheng Y; Peng Q; Xu Y; Luo Y; Wu Y; Zhu X
Med Sci Monit; 2019 Nov; 25():8579-8586. PubMed ID: 31724562
[TBL] [Abstract][Full Text] [Related]
15. Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.
Liu A; Takakuwa T; Luo WJ; Fujita S; Aozasa K
Cancer Sci; 2006 Jul; 97(7):605-10. PubMed ID: 16827800
[TBL] [Abstract][Full Text] [Related]
16. Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function.
Zhang H; Lu J; Jiao Y; Chen Q; Li M; Wang Z; Yu Z; Huang X; Yao A; Gao Q; Xie W; Li L; Yao P
Front Oncol; 2018; 8():679. PubMed ID: 30693272
[TBL] [Abstract][Full Text] [Related]
17. MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1.
Chang Y; Cui M; Fu X; Zhang L; Li X; Li L; Wu J; Sun Z; Zhang X; Li Z; Nan F; Yan J; Zhang M
Cancer Biol Ther; 2019; 20(1):31-41. PubMed ID: 30299211
[TBL] [Abstract][Full Text] [Related]
18. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
19. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
20. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
